X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (230) 230
humans (226) 226
male (164) 164
middle aged (163) 163
oncology (163) 163
female (162) 162
aged (161) 161
hematology (150) 150
adult (134) 134
abridged index medicus (98) 98
aged, 80 and over (89) 89
treatment outcome (88) 88
article (73) 73
leukemia, lymphocytic, chronic, b-cell - drug therapy (70) 70
chronic lymphocytic leukemia (67) 67
antineoplastic combined chemotherapy protocols - therapeutic use (64) 64
prognosis (60) 60
cancer (58) 58
rituximab (57) 57
therapy (51) 51
cll (49) 49
leukemia (46) 46
hemic and lymphatic diseases (41) 41
antineoplastic agents - therapeutic use (40) 40
disease-free survival (39) 39
hematology, oncology and palliative medicine (38) 38
antineoplastic combined chemotherapy protocols - adverse effects (37) 37
fludarabine (37) 37
survival (37) 37
care and treatment (35) 35
leukemia, lymphocytic, chronic, b-cell - genetics (35) 35
follow-up studies (34) 34
adolescent (32) 32
chemotherapy (32) 32
remission induction (32) 32
leukemia, lymphocytic, chronic, b-cell - mortality (31) 31
research (30) 30
vidarabine - analogs & derivatives (30) 30
young adult (30) 30
survival rate (29) 29
drug administration schedule (28) 28
acute myeloid-leukemia (26) 26
cyclophosphamide (26) 26
initial therapy (26) 26
leukemia, lymphocytic, chronic, b-cell - pathology (26) 26
patients (26) 26
retrospective studies (26) 26
recurrence (25) 25
chronic lymphocytic-leukemia (24) 24
cyclophosphamide - administration & dosage (24) 24
trial (24) 24
chemoimmunotherapy (22) 22
leukemia, lymphocytic, chronic, b-cell - therapy (22) 22
pyrimidines - therapeutic use (22) 22
chronic myelogenous leukemia (21) 21
cytarabine - administration & dosage (21) 21
drug therapy (21) 21
lymphoma (21) 21
survival analysis (21) 21
alemtuzumab (20) 20
disease progression (20) 20
chronic lymphatic leukemia (19) 19
kaplan-meier estimate (19) 19
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (19) 19
analysis (18) 18
antibodies, monoclonal - administration & dosage (18) 18
risk factors (18) 18
vidarabine - administration & dosage (18) 18
clinical trials and observations (17) 17
cytarabine (17) 17
diagnosis (17) 17
dose-response relationship, drug (17) 17
expression (17) 17
ibrutinib (17) 17
imatinib mesylate (17) 17
leukemia, lymphocytic, chronic, b-cell - diagnosis (17) 17
antibodies, monoclonal - therapeutic use (16) 16
antibodies, monoclonal, humanized (16) 16
antineoplastic combined chemotherapy protocols - administration & dosage (16) 16
dosage and administration (16) 16
leukemia, lymphocytic, chronic, b-cell - metabolism (16) 16
minimal residual disease (16) 16
acute disease (15) 15
antibodies, monoclonal, murine-derived (15) 15
antineoplastic agents - administration & dosage (15) 15
antineoplastic agents - adverse effects (15) 15
chronic myeloid-leukemia (15) 15
disease (15) 15
immune system diseases (15) 15
leukemia, lymphocytic, chronic, b-cell - immunology (15) 15
lymphoid neoplasia (15) 15
mutation (15) 15
myelodysplastic syndromes - drug therapy (15) 15
neoplasm staging (15) 15
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (15) 15
apoptosis (14) 14
cells (14) 14
chronic myeloid leukemia (14) 14
combination (14) 14
imatinib (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1090 - 1099
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S38 - S40
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 5, pp. 584 - 591
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2010, Volume 28, Issue 3, pp. 392 - 397
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2009, Volume 27, Issue 4, pp. 504 - 510
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2010, Volume 28, Issue 24, pp. 3880 - 3889
Journal Article
Cancer, ISSN 0008-543X, 03/2018, Volume 124, Issue 6, pp. 1160 - 1168
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 9, pp. 2154 - 2158
Background: Ibrutinib is an active therapy with an acceptable safety profile for patients with chronic lymphocytic leukemia (CLL), including high-risk patients... 
TRIAL | CLL | ONCOLOGY | INITIAL THERAPY | Therapy | Chronic lymphatic leukemia | Cell survival | Risk groups | Leukemia | p53 Protein | Medical treatment | Stem cell transplantation | Rituximab | Risk | Transplantation | Lymphatic leukemia | Survival | Patients | Clonal deletion | Experimental design | Safety engineering | Deletion | Remission | Fatalities | Mutation | Cancer | Index Medicus | deletion 17p | chronic lymphocytic leukemia | Ibrutinib | rituximab
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 240 - 248
Journal Article
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2010, Volume 2010, Issue 1, pp. 82 - 89
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2009, Volume 27, Issue 28, pp. 4760 - 4766
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2006, Volume 12, Issue 17, pp. 5165 - 5173
Purpose: Everolimus (RAD001, Novartis), an oral derivative of rapamycin, inhibits the mammalian target of rapamycin (mTOR), which regulates many aspects of... 
mTOR inhibitor | 4E-BP1 | hypoxia-inducible factor | chronic lymphocytic leukemia | p70S6K | myelodysplastic syndrome | WORKING GROUP | ONCOLOGY | CYCLIN D1 | OBLITERANS ORGANIZING PNEUMONIA | TEMSIROLIMUS CCI-779 | DOWN-REGULATION | ACUTE MYELOID-LEUKEMIA | TRANSPLANT RECIPIENTS | MTOR INHIBITORS | RENAL-CELL CARCINOMA | CANCER-THERAPY | Protein Kinases - metabolism | Recurrence | Phosphorylation | Humans | Leukemia, Prolymphocytic - drug therapy | Middle Aged | Leukemia, T-Cell - drug therapy | Vasculitis, Leukocytoclastic, Cutaneous - chemically induced | Male | Phosphoproteins - antagonists & inhibitors | Dose-Response Relationship, Drug | Adaptor Proteins, Signal Transducing - antagonists & inhibitors | Drug-Related Side Effects and Adverse Reactions | Killer Cells, Natural - immunology | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Everolimus | Myelodysplastic Syndromes - drug therapy | Sirolimus - adverse effects | Protein Kinases - drug effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Drug Administration Schedule | Administration, Oral | Ribosomal Protein S6 Kinases, 70-kDa - antagonists & inhibitors | Lymphoma, Mantle-Cell - drug therapy | Treatment Outcome | Sirolimus - administration & dosage | Maximum Tolerated Dose | Signal Transduction - drug effects | Adolescent | T-Lymphocytes - immunology | Aged | TOR Serine-Threonine Kinases | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Index Medicus
Journal Article